Vertex Pharmaceuticals (VRTX) Q1 2026 (USD): Adj. EPS 4.47 (exp. 4.24), Revenue 2.99bln (exp. 2.99bln)

Vertex Pharmaceuticals reported Q1 2026 adjusted EPS of 4.47, beating expectations of 4.24, indicating stronger-than-expected profitability. While revenue met estimates at 2.99 billion, the guidance for FY revenue is slightly lower than consensus, suggesting potential caution in growth outlook. This mixed result could influence market sentiment, particularly in the biotech sector, as investors assess the implications for future performance.